Novartis projects net sales to grow at a 5% compound annual growth rate in constant currencies from 2026 through 2031, as the Swiss drugmaker updates its growth outlook amid its largest loss-of-exclusivity impact to date.
The company said its core operating income margin is on track to return to at least 40% by 2029. Novartis announced the guidance Nov. 19, the day of its management event in London.
Novartis raised its potential peak-sales estimate for Kesimpta to $8 billion from $6 billion, and set estimates of $5 billion each for Scemblix and Leqvio, up from $4 billion each. The figures are potential peak sales, not current sales, and the company did not specify when the medicines might reach those levels.
The company said nine marketed medicines or medicine groups have peak-sales potential ranging from $3 billion to $10 billion. It also expects more than 35 readouts that could potentially support regulatory submissions through 2031, and said its development pipeline includes more than 30 potential high-value assets.
Novartis’ previous midterm guidance called for 5% to 6% annual net sales growth in constant currencies from 2025 through 2030. The updated outlook shifts the period forward and sets a single 5% growth rate. The company said its 2026 outlook accounts for the largest loss-of-exclusivity impact in its history, but did not quantify the effect.
Chief Executive Vas Narasimhan said late-stage Phase III programs, along with the company’s Phase I and II pipeline, support its confidence in sustaining mid-single-digit growth over the longer term. Novartis cautioned that investigational medicines may not be submitted for approval, receive approval or succeed commercially.
The sales-growth projection is a compound annual growth rate in constant currencies, and Novartis classifies constant-currency growth and core results as non-IFRS measures.


